Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2005:1–156. doi: 10.1007/3-540-26367-5_1

A

Editor: Peter Berlit1
PMCID: PMC7122271

The content is available as a PDF (1.6 MB).

Literatur

  • 1.Stefan H., Snead O.C., III . Absence seizures. In: Engel J. Jr, Peadley T., editors. Epilepsy. A comprehensive textbook. Philadelphia: Lippincott Raven Publishers; 1997. [Google Scholar]

Literatur

  • 1.Commission on ClassificationTerminology of the International League against Epilepsy Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989;30:389–399. doi: 10.1111/j.1528-1157.1989.tb05316.x. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Shapiro E.D., Gerber M.A., Holabird N.B., et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med. 1992;327:1769–73. doi: 10.1056/NEJM199212173272501. [DOI] [PubMed] [Google Scholar]
  • 2.Steere A.C., Sikand V.K., Meurice F., et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer surface protein lipoprotein A with adjuvant. N Engl J Med. 1998;339:209–15. doi: 10.1056/NEJM199807233390401. [DOI] [PubMed] [Google Scholar]
  • 3.Strie F. Principles of the diagnosis and antibiotic treatment of Lyme borreliosis. Wien Klin Wochenschr. 1999;111:911–915. [PubMed] [Google Scholar]

Literatur

  • 1.Harding A.E. The clinical features and classification of the late onset autosomal dominant cerebellar ataxias. A study of 11 families, including descendants of the Drew family of Walworth’. Brain. 1982;105:1–28. doi: 10.1093/brain/105.1.1. [DOI] [PubMed] [Google Scholar]
  • 2.Klockgether T., Bürk T., Dichgans J. Zerebelläre Bewegungsstörungen (Ataxien) In: Conrad B., Ceballos-Baumann A.O., editors. Bewegungsstörungen in der Neurologie. Stuttgart New York: Thieme; 1996. pp. 254–279. [Google Scholar]
  • 3.Tan E.-K., Ashizawa T. Genetic testing in spinocerebellar ataxias. Arch Neurol. 2001;58:191–195. doi: 10.1001/archneur.58.2.191. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Huber A., Kömpf D. Klinische Neuroophthalmologie. Stuttgart New York: Thieme; 1998. [Google Scholar]

Literatur

  • 1.Huber A., Kömpf D. Klinische Neuroophthalmologie. Stuttgart New York: Thieme; 1998. [Google Scholar]

Literatur

  • 1.Moser H.W. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain. 1997;120:1485–1508. doi: 10.1093/brain/120.8.1485. [DOI] [PubMed] [Google Scholar]
  • 2.Singh I., et al. Lovastatin for X-linked adrenoleukodystrophy. NEJM. 1998;339:702–703. doi: 10.1056/NEJM199809033391012. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Curran H.V., et al. Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agarophobia with panic disorder. Psychol Med. 1994;24:969–976. doi: 10.1017/S0033291700029056. [DOI] [PubMed] [Google Scholar]
  • 2.Mavissakalian M.R., Ryan M.T. Rational Treatment of Panic Disorder with Antidepressants. Ann Clin Psych. 1998;10:185–195. doi: 10.1023/a:1022302414638. [DOI] [PubMed] [Google Scholar]
  • 3.Van Balkom A., et al. A Meta-Analysis of the Treatment of Panic Disorders with or without Agoraphobia: A Comparison of Psychopharmacological, Cognitive-Behavioral and Combination Treatment. J Neur Ment Dis. 1997;185:510–516. doi: 10.1097/00005053-199708000-00006. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Baxter P.S., et al. Vigabatrin monotherapy in resistant neonatal seizures. Seizure. 1995;4(1):57–9. doi: 10.1016/S1059-1311(05)80080-9. [DOI] [PubMed] [Google Scholar]
  • 2.Talens C., et al. Early stimulation: psychomotor development of two girls with Aicardi syndrome. Child Care Health Dev. 1987;13(2):101–9. doi: 10.1111/j.1365-2214.1987.tb00527.x. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Feasby T.E., Gilbert J.J., Brown W.F., et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain. 1986;109:1115–1126. doi: 10.1093/brain/109.6.1115. [DOI] [PubMed] [Google Scholar]
  • 2.Flachenecker P., Reiners K. Twenty-fourhour heart rate power spectrum for evaluation of autonomic dysfunction in Guillain-Barre syndrome. J Neurol Sciences. 1999;165:144–153. doi: 10.1016/s0022-510x(99)00096-9. [DOI] [PubMed] [Google Scholar]
  • 3.Flachenecker P., Toyka K.V., Reiners K. Herzrhythmusstörungen beim Guillain-Barre-Syndrom. Nervenarzt. 2001;72:610–617. doi: 10.1007/s001150170060. [DOI] [PubMed] [Google Scholar]
  • 4.Hadden R.D.M., Cornblath D.R., Hughes R.A.C., et al. The Plasma exchange/Sandoglobin Guillain-Barre Syndrome Trial Group. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Ann Neurol. 1998;44:780–788. doi: 10.1002/ana.410440512. [DOI] [PubMed] [Google Scholar]
  • 5.Hartung H.P., Willison H.J., Kieseier B.C. Acute immunoinflammatory neuropathy: update on Guillain-Barre syndrome. Curr Opin Neurol. 2002;15(5):571–577. doi: 10.1097/00019052-200210000-00008. [DOI] [PubMed] [Google Scholar]
  • 6.Hughes R.A.C., Swan A.V., Cornblath D.R., et al. Randomised trials of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 1997;349:225–230. [PubMed] [Google Scholar]
  • 7.Rees J.H., Soudain S.E., Gregson N.A., Hughes R.A.C. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med. 1995;23:1374–1379. doi: 10.1056/NEJM199511233332102. [DOI] [PubMed] [Google Scholar]
  • 8.The Dutch Guillain-Barré Study Group Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: A pilot study. Ann Neurol. 1994;35:749–752. doi: 10.1002/ana.410350618. [DOI] [PubMed] [Google Scholar]
  • 9.The Guillain-Barré Study Group Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 1985;35:1096–1104. [PubMed] [Google Scholar]
  • 10.van der Meche F.G., Schmitz P.I., the Dutch Guillain-Barré Study Group A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barrésyndrome. N Engl J Med. 1992;326:1123–1129. doi: 10.1056/NEJM199204233261705. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Flachenecker P., Reiners K. Twenty-fourhour heart rate power spectrum for evaluation of autonomic dysfunction in Guillain-Barre syndrome. J Neurol Sciences. 1999;165:144–153. doi: 10.1016/S0022-510X(99)00096-9. [DOI] [PubMed] [Google Scholar]
  • 2.Flachenecker P., Toyka K.V., Reiners K. Herzrhythmusstörungen beim Guillain-Barre-Syndrom. Nervenarzt. 2001;72:610–617. doi: 10.1007/s001150170060. [DOI] [PubMed] [Google Scholar]
  • 3.Flachenecker P., Wermuth P., Hartung H.-P., Reiners K. Quantitative assessment of cardiovascular autonomic function in Guillain-Barré syndrome. Ann Neurol. 1997;42:171–179. doi: 10.1002/ana.410420207. [DOI] [PubMed] [Google Scholar]
  • 4.Hilz M.J., Claus D., Bauer J., Neundörfer B. Transcutaneous cardiac pacemaker for prevention and emergency therapy in neurologic intensive care patients. Nervenarzt. 1990;61(12):744–748. [PubMed] [Google Scholar]
  • 5.Pfeiffer G., Schiller B., Kruse J., Netzer J. Indicators of dysautonomia in severe Guillain Barre syndrome. J Neurol. 1999;246:1015–1022. doi: 10.1007/s004150050506. [DOI] [PubMed] [Google Scholar]
  • 6.Winer J.B., Hughes R.A.C. Identification of patients at risk of arrhythmia in the Guillain-Barré syndrome. Q J Med. 1988;257:735–739. [PubMed] [Google Scholar]

Literatur

  • 1.Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A (2000). Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults (Cochrane Review). The Cochrane Library, Issue 2, Oxford Update Software. [DOI] [PubMed]
  • 2.Rutherford GW, Feldman KA, Kennedy, GE (2000). Three-or four-versus two-drug antiretroviral maintenance regimens for HIV infection (Cochrane Review). The Cochrane Library, Issue 2, Oxford Update Software. [DOI] [PubMed]

Literatur

  • 1.Huber A., Kömpf D. Klinische Neuroophthalmologie. Stuttgart New York: Thieme; 1998. [Google Scholar]
  • 2.IONDT-group (ischemic optic neuropathy decompression trial search group) Optic nerve decompression surgery for NAION is not effective and may be harmful. JAMA. 1995;273:625–632. [PubMed] [Google Scholar]

Literatur

  • 1.Lumenta C.B., Brückmann H., Feldmann H.J., Strupp M.L., Wowra B. Neurinome. In: Tumorzentrum München, editor. Hirntumoren und primäre Tumoren des Rückenmarks. Empfehlungen zur Diagnostik, Therapie und Nachsorge. München Bern Wien New York: Zuckschwerdt; 2001. [Google Scholar]

Literatur

  • 1.Huber A., Kömpf D. Klinische Neuroophthalmologie. Stuttgart New York: Thieme; 1998. [Google Scholar]

Literatur

  • 1.Bou J., Domenech T., Puig J., et al. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol. 2000;410:33–41. doi: 10.1016/S0014-2999(00)00876-1. [DOI] [PubMed] [Google Scholar]
  • 2.Bou J., Domenech T., Gras J., et al. Pharmacological profile of almotriptan, a novel antimigraine drug. Cephalalgia. 1997;17:421–422. [Google Scholar]
  • 3.Gras J., Bou J., Llenas J., et al. Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol. 2000;410:43–51. doi: 10.1016/s0014-2999(00)00877-3. [DOI] [PubMed] [Google Scholar]
  • 4.Fernandez F.J., Cabarrocas X., Zayas J.M., et al. Oral almotriptan in the treatment of migraine. Cephalalgia. 1999;19:362–362. [Google Scholar]
  • 5.Pascual J. Therapy with other triptans: almotriptan. In: Diener H.C., editor. Drug treatment of migraine and other headaches. Basel: Karger; 2000. pp. 197–205. [Google Scholar]
  • 6.Pascual J., Falk R.M., Piessens F., et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, doubleblind, placebo-controlled study. Cephalalgia. 2000;20:588–596. doi: 10.1046/j.1468-2982.2000.00091.x. [DOI] [PubMed] [Google Scholar]
  • 7.Cabarrocas X., Zayas J.M. Efficacy data on oral almotriptan, a novel 5-HT1B/D agonist. Headache. 1998;38:377–378. [Google Scholar]
  • 8.Cabarrocas X., Zayas J.M. Advantageous tolerability of almotriptan 12,5 mg compared with sumatriptan 100 mg. Headache. 1999;39:347. [Google Scholar]
  • 9.Martinez E., Cabarrocas X., Peris F., et al. Meta-analysis of the efficacy and safety of almotriptan in the treatment of migraine. Cephalalgia. 1999;19:362. [Google Scholar]
  • 10.Pascual J, Falk RM, Docekal P et al. (2001) The tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol 45 (4) [DOI] [PubMed]
  • 11.Almirall Prodesfarma, Bayer Vital GmbH 12,5 mg Filmtablette (2000) Fachinformation November 2000
  • 12.Matthew N.T. Results of a 1-year open study on almotriptan. London: Headache World; 2000. [Google Scholar]

Literatur

  • 1.Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425–1431. doi: 10.1016/s0140-6736(96)91680-3. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Aisen, et al. A randomized trial of prednisone in Alzheimer’s disease. Neurology. 2000;54(3):588–593. doi: 10.1212/wnl.54.3.588. [DOI] [PubMed] [Google Scholar]
  • 2.Alastair J.J., Wood M.D. Treatment of Alzheimer’s Disease. The New England Journal of Medicine. 1999;341:1670–1679. doi: 10.1056/NEJM199911253412207. [DOI] [PubMed] [Google Scholar]
  • 3.Henderson, et al. Estrogen for Alzheimer’s disease in women. Randomized, double-blind, placebo-controlled trial. Neurology. 2000;54:295–301. doi: 10.1212/wnl.54.2.295. [DOI] [PubMed] [Google Scholar]
  • 4.Veld B.A., Ruitenberg A., Stricker B.H., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med. 2001;345:1515–1521. doi: 10.1056/NEJMoa010178. [DOI] [PubMed] [Google Scholar]
  • 5.Knapp M.J., Knopmann D.S., Soloman P.R., Pendlebury W.W., Davis C.S., Gracon SI. A. 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’disease. JAMA. 1994;271:985–991. doi: 10.1001/jama.271.13.985. [DOI] [PubMed] [Google Scholar]
  • 6.Le Bars P.L., Katz M.M., Berman N., Itil T.M., Freedmann A.M., Schatzberg A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginko biloba for dementia. JAMA. 1997;278:1327–1332. doi: 10.1001/jama.278.16.1327. [DOI] [PubMed] [Google Scholar]
  • 7.Raskind M.A., Peskind E.R., Wessel T., Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group Neurology. 2000;54(12):2261–8. doi: 10.1212/wnl.54.12.2261. [DOI] [PubMed] [Google Scholar]
  • 8.Rösler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer’disease: international randomized controlled trial. BMJ. 1999;318:633–638. doi: 10.1136/bmj.318.7184.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T. Donepezil study group. A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimers’ disease. Neurology. 1998;50:136–145. doi: 10.1212/wnl.50.1.136. [DOI] [PubMed] [Google Scholar]
  • 10.Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegeline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med. 1997;336:1216–1222. doi: 10.1056/NEJM199704243361704. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Huber A., Kömpf D. Klinische Neuroophthalmologie. Stuttgart New York: Thieme; 1998. [Google Scholar]

Literatur

  • 1.Kain Z., et al. Midazolam: effects on amnesia and anxiety in children. Anesthesiology. 2000;93:676–84. doi: 10.1097/00000542-200009000-00016. [DOI] [PubMed] [Google Scholar]
  • 2.Verwey B., et al. Memory impairment in those who attempted suicide by benzodiazepine overdose. J Clin Psychiatry. 2000;61:456–9. doi: 10.4088/jcp.v61n0612. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Mrazek M., et al. Therapeutische Erfahrungen beim alkoholbedingten Korsakow-Syndrom. Nervenarzt. 1999;70:790–794. doi: 10.1007/s001150050513. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Rösler A., et al. Precipitating factors of transient global amnesia. J Neurol. 1999;246:53–54. doi: 10.1007/s004150050306. [DOI] [PubMed] [Google Scholar]
  • 2.Berlit P. Successful prophylaxis of recurrent transient global amnesia with metoprolol. Neurology. 2000;55:1937–1938. doi: 10.1212/wnl.55.12.1937. [DOI] [PubMed] [Google Scholar]
  • 3.Zeman A.Z.J., Hodges J.R. Transient global amnesia. Br J Hosp Med. 1997;58:257–260. [PubMed] [Google Scholar]

Literatur

  • 1.Zeman A.Z., Boniface S.J., Hodges J.R. Transient epileptic amnesia: A description of the clinical and neuropsychological features in 10 cases and a review of the literature. J Neurol Neurosurg Psychiatry. 1998;4:435–443. doi: 10.1136/jnnp.64.4.435. [DOI] [PMC free article] [PubMed] [Google Scholar]

Literatur

  • 1.Gillmore J.D., Davies J., Iqbal A., Madhoo S., Russell N.H., Hawkins P.N. Allogenic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol. 1998;100:226–228. doi: 10.1046/j.1365-2141.1998.00527.x. [DOI] [PubMed] [Google Scholar]
  • 2.Kyle R.A., Dyck P.J. Amyloidosis and neuropathy. In: Dyck P.J., Thomas P.K., editors. Peripheral neuropathy. Philadelphia: WB Saunders Company; 1993. pp. 1294–1309. [Google Scholar]
  • 3.Kyle R.A., Gertz M.A., Greipp P.R., Witzig T.E., Lust J.A., Lacy M.Q., Therneau T.M. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202–1207. doi: 10.1056/NEJM199704243361702. [DOI] [PubMed] [Google Scholar]
  • 4.Moreau P., Leblond V., Bourquelot P., Facon T., Huynh A., Caillot D., et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation Amyloidose, in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101:766–769. doi: 10.1046/j.1365-2141.1998.00772.x. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.ISUIA Investigators Unruptured intracranial aneurysms — risk of rupture and risks of surgical intervention. The New England Journal of Medicine. 1998;24:1725–1733. doi: 10.1056/NEJM199812103392401. [DOI] [PubMed] [Google Scholar]
  • 2.Brilstra, et al. Treatment of intracranial aneurysms by embolization with coil: a systematic review. Stroke. 1999;30(2):470–476. doi: 10.1161/01.str.30.2.470. [DOI] [PubMed] [Google Scholar]
  • 3.Bederson, et al. Recommendations for the management of patients with unruptured intracranial aneurysma. Stroke. 2000;31:2742–2750. doi: 10.1161/01.str.31.11.2742. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Brilstra, et al. Treatment of intracranial aneurysms by embolization with coil: a systematic review. Stroke. 1999;30(2):470–476. doi: 10.1161/01.str.30.2.470. [DOI] [PubMed] [Google Scholar]
  • 2.ISAT (International Subarachnoid Aneurysm Trial) Lancet. 2002;360:1267–1274. doi: 10.1016/s0140-6736(02)11314-6. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Commission on ClassificationTerminology of the International League against Epilepsy Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22:489–501. doi: 10.1111/j.1528-1157.1981.tb06159.x. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Commission on ClassificationTerminology of the International League against Epilepsy Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22:489–501. doi: 10.1111/j.1528-1157.1981.tb06159.x. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Schiffmann R., Murray G.J., Treco D., Daniel P., Sellos-Moura M., Myers M., Quirk J.M., Zirzow G.C., Borowski M., Loveday K., Anderson T., Gillespie F., Oliver K.L., Jeffries N.O., Doo E., Liang T.J., Kreps C., Gunter K., Frei K., Crutchfield K., Selden R.F., Brady R.O. Infusion of alpha-galactosidase A reduces tissue globotriao-sylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA. 2000;97:365–370. doi: 10.1073/pnas.97.1.365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Abe A., Arend L.J., Lee L., Lingwood C., Brady R.O., Shayman J.A. Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase. Kidney Int. 2000;57:446–454. doi: 10.1046/j.1523-1755.2000.00864.x. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Krämer G. Epilepsien im höheren Lebensalter. Stuttgart, New York: Thieme; 1999. [Google Scholar]
  • 2.Stefan H. Epilepsien: Diagnose und Behandlung. Stuttgart, New York: Thieme; 1999. [Google Scholar]

Literatur

  • 1.Tunick P.A., et al. Am J Cardiol. 2002;90:1320–25. doi: 10.1016/S0002-9149(02)02870-9. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Penkert G., Carvalho G.A., Nikkhah G., Tatagiba M., Matthies C., Samii M. Diagnosis and surgery of brachial plexus injuries. J Reconstr Microsurg. 1999;15:3–8. doi: 10.1055/s-2007-1000063. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Berlit P. Clinical and laboratory findings with giant cell arteriitis. J Neurol Sci. 1992;III:1–12. doi: 10.1016/0022-510x(92)90105-t. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Kleihues P, Cavenee W (Hrsg.) (2000). Tumors of the Nervous System. WHO Classification of Tumours. IARC Press, Lyon.
  • 2.Schlegel U., Westpahl M., editors. Neuroonkologie. Stuttgart New York: Thieme; 1998. [Google Scholar]
  • 3.Walker M.D., Green S.B., Byar D.P., et al. Randomized comparisons of radiotherapy and nitrosureas for the treatment of malinant gliomas after surgery. New Engl J Med. 1980;303:1323–1329. doi: 10.1056/NEJM198012043032303. [DOI] [PubMed] [Google Scholar]
  • 4.Shaw E.G., Scheithauer B.W., O’Fallon J.R. Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol. 1997;31:273–278. doi: 10.1023/A:1005715703598. [DOI] [PubMed] [Google Scholar]
  • 5.Peraud A., Kreth F.W., Siefert A., et al. Niedermaligne Gliome. In: Tumorzentrum Münchenet al., editors. Hirntumoren und primäre Tumoren des Rückenmarks. Empfehlungen zur Diagnostik, Therapie und Nachsorge. München Bern Wien New York: Zuckschwerdt; 2001. [Google Scholar]
  • 6.Albert F.K., Forsting M., Sartor K., et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994;34:45–60. doi: 10.1097/00006123-199401000-00008. [DOI] [PubMed] [Google Scholar]
  • 7.Levin V.A., Silver P., Hannigan J., et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Rad Oncol Biol Phys. 1990;18:321–324. doi: 10.1016/0360-3016(90)90096-3. [DOI] [PubMed] [Google Scholar]
  • 8.Hildebrandt J., Sahmoud T., Mignolet F., et al. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology. 1994;44:1479–1483. doi: 10.1212/wnl.44.8.1479. [DOI] [PubMed] [Google Scholar]
  • 9.Thomas D.G.T., Bleehan N.M., Roberts J.T., et al. MRC randomised trial of adjuvant chemotherapy in high grade glioma (HGG)-BR05. J Neuro Oncol. 1998;39:102. [Google Scholar]
  • 10.Yung W.K., Prados M.D., Yaya-Tur R., et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762–71. doi: 10.1200/JCO.1999.17.9.2762. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Klockgether T., Bürck T., Dichgans J. Zerebelläre Bewegungsstörungen (Ataxien) In: Conrad B., Ceballos-Baumann A.O., editors. Bewegungsstörungen in der Neurologie. Stuttgart New York: Thieme; 1996. pp. 254–279. [Google Scholar]
  • 2.Tan E.-K., Ashizawa T. Genetic testing in spinocerebellar ataxias. Arch Neurol. 2001;58:191–195. doi: 10.1001/archneur.58.2.191. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Klockgether T., Bürk T., Dichgans J. Zerebelläre Bewegungsstörungen (Ataxien) In: Conrad B., Ceballos-Baumann A.O., editors. Bewegungsstörungen in der Neurologie. Stuttgart New York: Thieme; 1996. pp. 254–279. [Google Scholar]
  • 2.Tan E.K., Ashizawa T. Genetic testing in spinocerebellar ataxias. Arch Neurol. 2001;58:191–195. doi: 10.1001/archneur.58.2.191. [DOI] [PubMed] [Google Scholar]

Literatur

  • 1.Huber A., Kömpf D. Klinische Neuroophthalmologie. Stuttgart New York: Thieme; 1998. [Google Scholar]

Literatur

  • 1.Confavreux C., Saddier P., Grimaud J., et al. Risk of cancer from azathioprine therapy in multiple sclerosis. A. case-control study. Neurology. 1996;46:1607–1612. doi: 10.1212/wnl.46.6.1607. [DOI] [PubMed] [Google Scholar]
  • 2.MS-Therapie Konsensus Gruppe (MSTKG) Immunmodulatorische Stufentherapie der Multiplen Sklerose. Nervenarzt. 1999;70:371–386. [PubMed] [Google Scholar]
  • 3.MS-Therapie Konsensus Gruppe (MSTKG) Immunmodulatorische Stufentherapie der Multiplen Sklerose. I. Ergänzung Dezember 2000. Nervenarzt. 2001;72:150–157. doi: 10.1007/s001150050729. [DOI] [PubMed] [Google Scholar]
  • 4.Pette M. Immunsuppressive, immunmodulatorische Therapie. In: Zettl U.K., Mix E., editors. Klinische Neuroimmunlogie. Berlin-New York: Verlag de Gruyter; 1999. pp. 261–276. [Google Scholar]
  • 5.Tolkoff-Rubin N.E., Rubin R.H., et al. The purin antagonists: Azathioprine and mycophenolat mofetil. In: Austen K.F., Burakoff S.J., Rosen F.S., et al., editors. Therapeutic Immunology. Cambridge: Blachwell sciences; 1996. pp. 44–56. [Google Scholar]

Articles from Therapielexikon Neurologie are provided here courtesy of Nature Publishing Group

RESOURCES